FDA announces new plans to combat opioid crisis
The U.S. Food and Drugs Administration (FDA) has announced two new plans to help combat the opioid crisis The first is a newly revised Risk Evaluation and Mitigation Strategy (REMS) blueprint for prescriber education. The 13-page document, titled “Opioid Analgesic REMS Education Blue Print for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain,” focuses on what prescribers should learn about managing acute and chronic pain.


